You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSuccinylcholine
Accession NumberDB00202  (APRD00159)
TypeSmall Molecule
GroupsApproved
DescriptionA quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for. [PubChem]
Structure
Thumb
Synonyms
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
Dicholine succinate
Succinic acid, diester with choline
Succinocholine
Succinoylcholine
Succinylbischoline
Succinylcholine
Succinyldicholine
Suxamethonium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnectineInjection, solution20 mg/mLIntramuscular; Intravenous; ParenteralSandoz Inc1952-08-20Not applicableUs
Anectine Flopack 500mgPowder, for solution500 mgIntravenousGlaxo Wellcome Inc.1959-12-311998-11-03Canada
Anectine Inj 20mg/mlLiquid20 mgIntravenousGlaxo Wellcome Inc.1952-12-312000-01-19Canada
QuelicinInjection, solution20 mg/mLIntramuscular; IntravenousHospira, Inc.1953-05-01Not applicableUs
Quelicin Chloride 100mg/mlSolution100 mgIntravenousHospira Healthcare Corporation1976-12-31Not applicableCanada
Quelicin Chloride Inj 20mg/mlSolution20 mgIntravenousHospira Healthcare Corporation1952-12-31Not applicableCanada
Quelicin Inj 20mg/ml USPSolution20 mgIntramuscular; IntravenousAbbott Laboratories, Limited1985-12-312009-12-14Canada
Succinylcholine Chloride InjectionSolution20 mgIntravenousTeligent Ou2014-09-30Not applicableCanada
Succinylcholine Chloride Injection USPSolution20 mgIntravenousMylan Pharmaceuticals Ulc1996-11-12Not applicableCanada
Succinylcholine Chloride Injection, USP 20mg/mlLiquid20 mgIntravenousAlveda Pharmaceuticals Inc2012-09-13Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Succinylcholine ChlorideInjection, solution20 mg/mLIntravenousCantrell Drug Company2015-03-12Not applicableUs
International Brands
NameCompany
ScolineNot Available
SucostrinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Succinylcholine Chloride
71-27-2
Thumb
  • InChI Key: YOEWQQVKRJEPAE-UHFFFAOYSA-L
  • Monoisotopic Mass: 360.158262872
  • Average Mass: 361.305
DBSALT000206
Categories
UNIIJ2R869A8YF
CAS number306-40-1
WeightAverage: 290.399
Monoisotopic: 290.220557458
Chemical FormulaC14H30N2O4
InChI KeyAXOIZCJOOAYSMI-UHFFFAOYSA-N
InChI
InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
IUPAC Name
trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium
SMILES
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
Pharmacology
IndicationUsed in surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ECT)
Structured Indications Not Available
PharmacodynamicsSuccinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine is a depolarizing skeletal muscle relaxant. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the receptor site. Succinylcholine has no direct action on the uterus or other smooth muscle structures.
Mechanism of actionThe mechanism of action of Succinylcholine involves what appears to be a "persistent" depolarization of the neuromuscular junction. This depolarization is caused by Succinylcholine mimicking the effect of acetylcholine but without being rapidly hydrolysed by acetylcholinesterase. This depolarization leads to desensitization.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuronal acetylcholine receptor subunit alpha-10Proteinyes
agonist
HumanQ9GZZ6 details
Alpha-7 nicotinic cholinergic receptor subunitProteinyes
agonist
HumanQ693P7 details
Muscarinic acetylcholine receptor M1Proteinyes
agonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
agonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
agonist
HumanP20309 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

By pseudocholinesterase, to succinylmonocholine and choline.

Route of eliminationAbout 10% of the drug is excreted unchanged in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Succinylcholine can be increased when it is combined with 1,10-Phenanthroline.Experimental
AcetyldigitoxinSuccinylcholine may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Succinylcholine.Investigational
AlfentanilSuccinylcholine may increase the bradycardic activities of Alfentanil.Approved, Illicit
AlphacetylmethadolSuccinylcholine may increase the bradycardic activities of Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe serum concentration of Succinylcholine can be increased when it is combined with Ambenonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
annamycinannamycin may increase the respiratory depressant activities of Succinylcholine.Investigational
AnvirzelSuccinylcholine may increase the arrhythmogenic activities of Anvirzel.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Succinylcholine.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Succinylcholine.Approved
BambuterolThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Bambuterol.Approved
BezitramideSuccinylcholine may increase the bradycardic activities of Bezitramide.Experimental, Illicit, Withdrawn
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
Botulinum Toxin Type BSuccinylcholine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
BuprenorphineSuccinylcholine may increase the bradycardic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolSuccinylcholine may increase the bradycardic activities of Butorphanol.Approved, Illicit, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Succinylcholine.Approved
CarfentanilSuccinylcholine may increase the bradycardic activities of Carfentanil.Illicit, Vet Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
CodeineSuccinylcholine may increase the bradycardic activities of Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
CoumaphosThe serum concentration of Succinylcholine can be increased when it is combined with Coumaphos.Vet Approved
CyclophosphamideThe serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational, Vet Approved
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Succinylcholine.Approved
DecamethoniumThe serum concentration of Succinylcholine can be increased when it is combined with Decamethonium.Approved
DemecariumThe serum concentration of Succinylcholine can be increased when it is combined with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Succinylcholine.Approved
DeslanosideSuccinylcholine may increase the arrhythmogenic activities of Deslanoside.Approved
DextromoramideSuccinylcholine may increase the bradycardic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneSuccinylcholine may increase the bradycardic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineSuccinylcholine may increase the bradycardic activities of Dezocine.Approved
DichlorvosThe serum concentration of Succinylcholine can be increased when it is combined with Dichlorvos.Vet Approved
DigitoxinSuccinylcholine may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinSuccinylcholine may increase the arrhythmogenic activities of Digoxin.Approved
DihydrocodeineSuccinylcholine may increase the bradycardic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineSuccinylcholine may increase the bradycardic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineSuccinylcholine may increase the bradycardic activities of Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Succinylcholine.Vet Approved
DiphenoxylateSuccinylcholine may increase the bradycardic activities of Diphenoxylate.Approved, Illicit
DonepezilThe serum concentration of Succinylcholine can be increased when it is combined with Donepezil.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational, Vet Approved
DPDPESuccinylcholine may increase the bradycardic activities of DPDPE.Investigational
EchothiophateThe serum concentration of Succinylcholine can be increased when it is combined with Echothiophate.Approved
EdrophoniumThe serum concentration of Succinylcholine can be increased when it is combined with Edrophonium.Approved
EpirubicinEpirubicin may increase the respiratory depressant activities of Succinylcholine.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Succinylcholine.Approved
EthylmorphineSuccinylcholine may increase the bradycardic activities of Ethylmorphine.Approved, Illicit
EtorphineSuccinylcholine may increase the bradycardic activities of Etorphine.Illicit, Vet Approved
FentanylSuccinylcholine may increase the bradycardic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe serum concentration of Succinylcholine can be increased when it is combined with Fenthion.Vet Approved
FramycetinFramycetin may increase the respiratory depressant activities of Succinylcholine.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
GalantamineThe serum concentration of Succinylcholine can be increased when it is combined with Galantamine.Approved
Gallamine TriethiodideThe serum concentration of Succinylcholine can be increased when it is combined with Gallamine Triethiodide.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Succinylcholine.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Succinylcholine.Experimental
Ginkgo bilobaThe serum concentration of Succinylcholine can be increased when it is combined with Ginkgo biloba.Approved, Nutraceutical
HeroinSuccinylcholine may increase the bradycardic activities of Heroin.Approved, Illicit
Huperzine AThe serum concentration of Succinylcholine can be increased when it is combined with Huperzine A.Investigational
HydrocodoneSuccinylcholine may increase the bradycardic activities of Hydrocodone.Approved, Illicit
HydromorphoneSuccinylcholine may increase the bradycardic activities of Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Succinylcholine.Vet Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Succinylcholine.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Succinylcholine.Investigational
IsoflurophateThe serum concentration of Succinylcholine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
KanamycinKanamycin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
KetobemidoneSuccinylcholine may increase the bradycardic activities of Ketobemidone.Approved
Levomethadyl AcetateSuccinylcholine may increase the bradycardic activities of Levomethadyl Acetate.Approved
LevorphanolSuccinylcholine may increase the bradycardic activities of Levorphanol.Approved
LithiumLithium may increase the neuromuscular blocking activities of Succinylcholine.Approved
LofentanilSuccinylcholine may increase the bradycardic activities of Lofentanil.Illicit
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Succinylcholine.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Succinylcholine.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Succinylcholine.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
MalathionThe serum concentration of Succinylcholine can be increased when it is combined with Malathion.Approved, Investigational
MefloquineThe serum concentration of Succinylcholine can be increased when it is combined with Mefloquine.Approved
MemantineThe serum concentration of Succinylcholine can be increased when it is combined with Memantine.Approved, Investigational
MethadoneSuccinylcholine may increase the bradycardic activities of Methadone.Approved
Methadyl AcetateSuccinylcholine may increase the bradycardic activities of Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe serum concentration of Succinylcholine can be increased when it is combined with Methanesulfonyl Fluoride.Investigational
MetrizamideMetrizamide may increase the respiratory depressant activities of Succinylcholine.Approved
MinaprineThe serum concentration of Succinylcholine can be increased when it is combined with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
MorphineSuccinylcholine may increase the bradycardic activities of Morphine.Approved, Investigational
NalbuphineSuccinylcholine may increase the bradycardic activities of Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Succinylcholine.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
NeostigmineThe serum concentration of Succinylcholine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Succinylcholine.Approved
NormethadoneSuccinylcholine may increase the bradycardic activities of Normethadone.Approved, Illicit
OpiumSuccinylcholine may increase the bradycardic activities of Opium.Approved, Illicit
OuabainSuccinylcholine may increase the arrhythmogenic activities of Ouabain.Approved
OxycodoneSuccinylcholine may increase the bradycardic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneSuccinylcholine may increase the bradycardic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
PentazocineSuccinylcholine may increase the bradycardic activities of Pentazocine.Approved, Vet Approved
PethidineSuccinylcholine may increase the bradycardic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the neuromuscular blocking activities of Succinylcholine.Approved
PhysostigmineThe serum concentration of Succinylcholine can be increased when it is combined with Physostigmine.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Succinylcholine.Investigational
PiretanidePiretanide may decrease the neuromuscular blocking activities of Succinylcholine.Experimental
PiritramideSuccinylcholine may increase the bradycardic activities of Piritramide.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Succinylcholine.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
ProcainamideProcainamide may increase the neuromuscular blocking activities of Succinylcholine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Succinylcholine.Experimental
PyridostigmineThe serum concentration of Succinylcholine can be increased when it is combined with Pyridostigmine.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Succinylcholine.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Succinylcholine.Approved
RemifentanilSuccinylcholine may increase the bradycardic activities of Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Succinylcholine.Approved
RivastigmineThe serum concentration of Succinylcholine can be increased when it is combined with Rivastigmine.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Succinylcholine.Investigational
SP1049CSP1049C may increase the respiratory depressant activities of Succinylcholine.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Succinylcholine.Approved
SufentanilSuccinylcholine may increase the bradycardic activities of Sufentanil.Approved, Investigational
TacrineThe serum concentration of Succinylcholine can be increased when it is combined with Tacrine.Withdrawn
TapentadolSuccinylcholine may increase the bradycardic activities of Tapentadol.Approved
TetracyclineTetracycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
TobramycinTobramycin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
TorasemideTorasemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
TramadolSuccinylcholine may increase the bradycardic activities of Tramadol.Approved, Investigational
TrichlorfonThe serum concentration of Succinylcholine can be increased when it is combined with Trichlorfon.Vet Approved
TubocurarineThe serum concentration of Succinylcholine can be increased when it is combined with Tubocurarine.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Succinylcholine.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Succinylcholine.Approved
ZorubicinZorubicin may increase the respiratory depressant activities of Succinylcholine.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Walter Raml, Gunther Eichberger, “Process for the preparation of succinylcholine halides.” U.S. Patent US5206420, issued April 27, 1993.

US5206420
General References
  1. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33. [PubMed:16571968 ]
External Links
ATC CodesM03AB01
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (75.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9962
Blood Brain Barrier+0.7717
Caco-2 permeable+0.5871
P-glycoprotein substrateSubstrate0.5916
P-glycoprotein inhibitor INon-inhibitor0.9036
P-glycoprotein inhibitor IINon-inhibitor0.8503
Renal organic cation transporterNon-inhibitor0.7974
CYP450 2C9 substrateNon-substrate0.8434
CYP450 2D6 substrateNon-substrate0.8173
CYP450 3A4 substrateNon-substrate0.5158
CYP450 1A2 substrateNon-inhibitor0.936
CYP450 2C9 inhibitorNon-inhibitor0.9381
CYP450 2D6 inhibitorNon-inhibitor0.9278
CYP450 2C19 inhibitorNon-inhibitor0.9142
CYP450 3A4 inhibitorNon-inhibitor0.9281
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9831
Ames testNon AMES toxic0.8556
CarcinogenicityCarcinogens 0.5298
BiodegradationReady biodegradable0.7156
Rat acute toxicity2.3010 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9012
hERG inhibition (predictor II)Non-inhibitor0.8418
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sandoz canada inc
  • Hospira inc
  • International medication systems ltd
  • Organon usa inc
  • Apothecon inc div bristol myers squibb
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous; Parenteral20 mg/mL
Powder, for solutionIntravenous500 mg
Injection, solutionIntramuscular; Intravenous20 mg/mL
SolutionIntravenous100 mg
SolutionIntravenous20 mg
SolutionIntramuscular; Intravenous20 mg
Injection, solutionIntravenous20 mg/mL
LiquidIntravenous20 mg
Prices
Unit descriptionCostUnit
Succinylcholine-ns 140 mg/7 ml2.08USD ml
Quelicin 100 mg/ml vial1.2USD ml
Quelicin 20 mg/ml vial0.22USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000757 mg/mLALOGPS
logP-2.5ALOGPS
logP-8.4ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)-6.8ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity100.94 m3·mol-1ChemAxon
Polarizability33.15 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acyl cholines. These are acylated derivatives of choline. Choline or 2-Hydroxy-N,N,N-trimethylethanaminium is a quaternary ammonium salt with the chemical formula (CH3)3N+(CH2)2OH.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassQuaternary ammonium salts
Sub ClassCholines
Direct ParentAcyl cholines
Alternative Parents
Substituents
  • Acyl choline
  • Fatty acid ester
  • Fatty acyl
  • Dicarboxylic acid or derivatives
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33. [PubMed:16571968 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
CHRNA7
Uniprot ID:
Q693P7
Molecular Weight:
2987.635 Da
References
  1. Rogers KR, Fernando JC, Thompson RG, Valdes JJ, Eldefrawi ME: Detection of nicotinic receptor ligands with a light addressable potentiometric sensor. Anal Biochem. 1992 Apr;202(1):111-6. [PubMed:1621972 ]
  2. Fiacchino F, Ariano C, Gemma M, Cerrato D: Abnormal responses to succinylcholine and pancuronium in a patient with hemiparesis. Ital J Neurol Sci. 1990 Oct;11(5):497-9. [PubMed:2272786 ]
  3. Marshall CG, Ogden DC, Colquhoun D: The actions of suxamethonium (succinyldicholine) as an agonist and channel blocker at the nicotinic receptor of frog muscle. J Physiol. 1990 Sep;428:155-74. [PubMed:2133043 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fisher DM: Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm. 1999 Jun 1;56(11 Suppl 1):S4-9. [PubMed:10437710 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50. [PubMed:9523819 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50. [PubMed:9523819 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Ostergaard D, Engbaek J, Viby-Mogensen J: Adverse reactions and interactions of the neuromuscular blocking drugs. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):351-68. [PubMed:2682131 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23